XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Product revenues $ 467 $ 731 $ 2,027 $ 3,190
Cost of product revenues 181 561 992 1,533
Amortization of intangible assets 306 57 919 237
Gross (loss) profit (20) 113 116 1,420
Development revenues:        
Government contracts and other 1,306 1,879 2,856 5,163
Total development revenues 1,306 1,879 2,856 5,163
Operating expenses:        
Research and development 3,004 3,960 9,284 13,334
Sales and marketing 840 818 3,043 2,742
General and administrative 1,785 2,011 6,012 6,623
Total operating expenses 5,629 6,789 20,025 22,699
Operating loss (4,343) (4,797) (17,053) (16,116)
Other income (expense):        
Interest income 5 4 24 8
Interest expense (474) (645) (1,603) (1,947)
Other income, net 5 54 233 928
Total other expense (464) (587) (1,346) (1,011)
Net loss $ (4,807) $ (5,384) $ (18,399) $ (17,127)
Basic and diluted net loss per share $ (0.14) $ (0.26) $ (0.62) $ (1.06)
Basic and diluted weighted average shares used in calculating net loss per share 34,490,828 20,493,840 29,564,032 16,147,042
Comprehensive loss:        
Net loss $ (4,807) $ (5,384) $ (18,399) $ (17,127)
Other comprehensive loss – foreign currency translation adjustments 16 58 (59) (321)
Comprehensive loss $ (4,791) $ (5,326) (18,458) (17,448)
Azaya Therapeutics, Inc. [Member]        
Operating expenses:        
In process research and development acquired     $ 1,686 $ 0